Alzheimer's Research To Be More Collaborative, Better Funded Under National Plan Most of the additional money will help support two trials - one for insulin as a treatment and one for crenezumab as a preventative. The Obama administration formally launched its national Alzheimer's plan in the midst of a two-day meeting that underscored how little researchers know about the disease.
Cornerstone Buys EKR Therapeutics To Expand Hospital Growth Strategy Cornerstone gains two commercial products for the acute-care hospital setting, Cardene and Retavase, with the acquisition of EKR Therapeutics for $125 million upfront and potential milestones.
Benlysta And Fampyra Fail to Make Headway As IQWiG Tightens Comparator Screw Germany's health technology evaluator's rejection of GSK's Benlysta and Biogen Idec's Fampyra could force companies to design separate trials for authorization and HTA assessment.
Pixuvri's Conditional EU Approval Could Herald The Rise Of Staggered Approval CTI's conditional EU approval for its non-Hodgkin B-cell lymphoma drug Pixuvri goes against the run of the drug in the US, but reinforces the idea that staggered approvals are on the way in Europe.
ESAs And Transfusions In Dialysis Patients: Watching For The Tipping Point A study from the U.S. Renal Data System contributes to concerns that decreasing use of erythropoiesis-stimulating agents like Amgen's Epogen in dialysis patients can lead to a significant increase in the need for blood transfusions.
